Journal September 16, 2026 6 min read

Cerebrolysin: what it is studied alongside

Cerebrolysin is a multimodal neuropeptide preparation studied as an adjunct to thrombectomy, thrombolysis, speech-language therapy, and virtual reality neurorehabilitation. This page summarises the research models and me

peptides-pro Editorial

Cerebrolysin is a multimodal neuropeptide preparation derived from porcine brain, studied primarily as an adjunct to reperfusion therapies and neurorehabilitation in ischaemic stroke. It is not a single molecular entity; the evidence block does not provide a sequence, formula, or molecular weight, and the preparation is described in the literature as a multimodal neuropeptide preparation rather than a defined small molecule [9]. The work centres on neuroprotection, neuroplasticity, and preservation of the blood-brain barrier and cerebral endothelial integrity.

Across the studies summarised here, Cerebrolysin has been investigated alongside endovascular thrombectomy, intravenous thrombolysis, speech-language therapy, and virtual reality neurorehabilitation. Several of the supporting papers are case reports or conference abstracts, and one line of evidence is in vitro. Where a finding is animal-only or in vitro, this is stated plainly.

Research Studies

Cerebrolysin and extended-window endovascular thrombectomy in acute ischaemic stroke

An ongoing multicentre randomised clinical trial is evaluating whether Cerebrolysin, given after successful extended-window endovascular thrombectomy, can reduce brain tissue injury and support recovery [1]. The trial addresses a specific gap: endovascular thrombectomy can benefit selected patients treated 6 to 24 hours after stroke onset, but some patients remain disabled even when the blocked artery is successfully reopened. Ongoing injury to brain tissue, small blood vessels, and the blood-brain barrier may contribute to this incomplete recovery [1]. The study population is patients with acute ischaemic stroke caused by large-artery occlusion who have undergone successful extended-window thrombectomy.

Cerebrolysin and mechanical thrombectomy in acute basilar artery occlusion

A case report described a 67-year-old woman with multiple vascular risk factors who presented with acute basilar artery occlusion and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction grade 3), with adjunctive Cerebrolysin administered subsequently [2]. Rapid neurological improvement was observed within 24 hours, with the National Institutes of Health Stroke Scale score decreasing from 7 to 2, followed by complete neurological recovery (NIHSS 0) [2]. Basilar artery occlusion is an uncommon yet devastating cause of posterior circulation stroke, frequently resulting in severe disability or death despite successful reperfusion [2]. This is a single case report; it does not establish efficacy.

Cerebrolysin and speech-language therapy in post-stroke Wernicke's aphasia

A case report described a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis following an ischaemic stroke [3]. Despite timely thrombolysis and mechanical thrombectomy, she experienced significant neurological deficits. Early multidisciplinary rehabilitation, combined with a 10-day course of Cerebrolysin, was associated with recovery [3]. Post-stroke aphasia affects approximately one-third of stroke survivors and impairs communication, social participation, and quality of life; speech-language therapy remains the standard of care, and pharmacological agents such as Cerebrolysin may enhance recovery through neuroprotection and neuroplasticity [3]. This is a single case report.

Cerebrolysin and speech therapy in nonfluent aphasia: meta-analysis

A conference abstract reports a meta-analysis of the effect of Cerebrolysin combined with speech therapy on nonfluent aphasia recovery after ischaemic stroke [6]. The evidence block does not provide the pooled effect size, the number of included studies, or the participant count. The abstract is indexed under ESOC2026A102.

Cerebrolysin and virtual reality neurorehabilitation in acute stroke

A conference abstract reports on virtual reality neurorehabilitation in acute stroke patients and the add-on effect of Cerebrolysin [7]. The evidence block does not provide outcome values or participant numbers. The abstract is indexed under ESOC2026A822.

Cerebrolysin after endovascular thrombectomy: 12-month functional outcomes

A conference abstract reports 12-month functional outcomes in a propensity-matched cohort of patients who received Cerebrolysin after endovascular thrombectomy in stroke [8]. The evidence block does not provide the effect estimates or cohort size. The abstract is indexed under ESOC2026A562.

Cerebrolysin and cerebral endothelial cell permeability: in vitro exosome study

An in vitro study tested whether exosomes released by Cerebrolysin-treated cerebral endothelial cells (Cerebro-Exos) affect dysfunctional cerebral endothelial cells [4]. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes derived from cerebral endothelial cells without Cerebrolysin treatment (Naïve-Exos); Cerebro-Exos were highly enriched with metabolic and tight junction related proteins compared to Naïve-Exos [4]. Cerebro-Exos had a superior effect compared to Naïve-Exos on restoring cerebral endothelial cell integrity impaired by fibrin and tissue plasminogen activator [4]. This is an in vitro endothelial permeability assay; it does not establish effects in humans.

Cerebrolysin and very early short-course administration after tenecteplase and mechanical thrombectomy

A case report described an 88-year-old woman who received a very early short course of Cerebrolysin after tenecteplase and mechanical thrombectomy [9]. The report notes that despite high recanalisation rates with mechanical thrombectomy, large-vessel occlusion stroke results in death or dependency in over half of patients, and that Cerebrolysin, a multimodal neuropeptide preparation, may attenuate ischaemia-reperfusion injury and support early neurorehabilitation [9]. This is a single case report.

Retracted findings in animal and preclinical models

Several preclinical findings involving Cerebrolysin have been retracted and should not be relied upon. These include a retraction note concerning Cerebrolysin and exacerbation of neuropathic pain, blood-spinal cord barrier breakdown, and cord pathology following chronic intoxication with engineered silver, copper, or aluminium nanoparticles (50-60 nm) [5]; a retraction concerning regional comparison of the neurogenic effects of CNTF-derived peptides and Cerebrolysin in AβPP transgenic mice [10]; a retraction note concerning timed release of Cerebrolysin using drug-loaded titanate nanospheres in a Parkinson's disease model [11]; and a retraction note concerning neurotrophic effects of Cerebrolysin in the Mecp2^308/Y transgenic model of Rett syndrome [12]. These retractions are noted here because they affect how the preclinical literature should be read.

Comparison of study designs and populations

Study	Design	Population	Adjunct
[1]	Multicentre randomised clinical trial (ongoing)	Acute ischaemic stroke, large-artery occlusion, extended-window thrombectomy	Endovascular thrombectomy
[2]	Case report	67-year-old woman, acute basilar artery occlusion	Intravenous thrombolysis and mechanical thrombectomy
[3]	Case report	38-year-old woman, post-stroke Wernicke's aphasia	Speech-language therapy and multidisciplinary rehabilitation
[6]	Meta-analysis (conference abstract)	Nonfluent aphasia after ischaemic stroke	Speech therapy
[7]	Conference abstract	Acute stroke patients	Virtual reality neurorehabilitation
[8]	Propensity-matched cohort (conference abstract)	Stroke patients after endovascular thrombectomy	Endovascular thrombectomy
[4]	In vitro endothelial permeability assay	Cerebral endothelial cells	None (exosome transfer)
[9]	Case report	88-year-old woman, large-vessel occlusion stroke	Tenecteplase and mechanical thrombectomy

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.